Pancreatic Cancer Screening Blood Test (EG-Pancreatic Blood Test-E1)
EG-Pancreatic Blood Test-E1 is an innovative, non-invasive early detection tool for pancreatic cancer. Using DNA methylation technology, it only requires 8 milliliters of blood to assess early cancer risk, enabling earlier detection and timely treatment to improve outcomes and survival rates.
Target Audience
- Diabetic patients (leading to pancreatic dysfunction)
- Those with a history of pancreatic cancer
- Patients with chronic pancreatitis
- Individuals with a family history of pancreatic cancer (such as mutations in BRCA1, BRCA2, or PALB2 genes)
- Those with abnormal tumor markers (such as elevated CA19-9 levels)
Clinical Analysis: Over 100 Cases
Early detection of pancreatic cancer (Stage I, II, III, IV)
Sensitivity: >99%
Specificity: 93.3%
Accuracy: 94.2%
Certifications and Approvals
🏆 Certified with ISO 15189 and LDTs standards. 🏆
A New Approach to Early Pancreatic Cancer Diagnosis
Pancreatic cancer often has no symptoms early on and is mistaken for common issues like fatigue or loss of appetite, leading many patients to miss the best treatment window.
Using DNA methylation technology, this non-invasive test enables early detection, providing valuable treatment time and improving survival rates and quality of life.
